Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Antineoplastics/lamivudine

Occult hepatitis B infection reactivation and lack of efficacy: 19 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Giordano C, et al. Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21. Frontiers in Oncology 13: Jan 2023. Available from: URL: http://www.frontiersin.org/Oncology/about Giordano C, et al. Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21. Frontiers in Oncology 13: Jan 2023. Available from: URL: http://​www.​frontiersin.​org/​Oncology/​about
Metadaten
Titel
Antineoplastics/lamivudine
Occult hepatitis B infection reactivation and lack of efficacy: 19 case reports
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-38302-9

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Nivolumab

Case report

AZD-1222